prnewswire.com web signal

WIRobotics Raises $68M to Scale ALLEX Humanoid Robot

robotics funding nvidia humanoid-robots robotics-funding embodied-ai

Key insights

  • WIRobotics has shipped over 3,000 WIM exoskeleton units commercially across four international markets before its humanoid platform launches.
  • Q1 2026 revenue alone surpassed all of 2024, suggesting the exoskeleton business is accelerating sharply heading into the humanoid push.
  • ALLEX humanoid mass production is targeted for 2027, with a research-focused version arriving later in 2026.

Why this matters

WIRobotics represents a structurally different humanoid bet: one where a profitable adjacent product (exoskeletons) funds the development runway rather than pure venture subsidy, which changes the survival calculus significantly compared to burn-only humanoid startups. The Nvidia and AWS backing signals that compute infrastructure partners are actively seeding the hardware layer of the robotics stack internationally, not just in US-headquartered firms. For technical leaders evaluating the humanoid space, the 2027 mass-production target from a company with live commercial deployments is a credible near-term benchmark against which to measure the broader field.

Summary

WIRobotics has closed a $68M Series B to push its dual-track robotics strategy: a wearable exoskeleton line already generating real revenue, and an emerging humanoid platform still finding its footing. The Seoul-based company pulled in KRW 95 billion led by JB Investment, with InterVest, Hana Ventures, SBVA, and NH Investment participating. The capital backs two distinct product lines: the WIM exoskeleton, which has shipped over 3,000 units commercially across Europe, China, Turkey, and Japan, and the ALLEX humanoid platform, targeting a research-oriented launch later in 2026 with mass production slated for 2027. WIRobotics has also opened a North American office in California and is working with Nvidia and AWS on infrastructure. Essentially: (WIRobotics, JB Investment) are betting that exoskeleton revenue can fund the longer runway humanoid development requires. - Revenue more than doubled annually through 2025, and Q1 2026 alone exceeded all of full-year 2024 revenue. - The Nvidia and AWS collaborations suggest WIRobotics is positioning ALLEX as a software and compute play, not just hardware. - The 2027 mass-production target puts WIRobotics on a timeline competitive with Figure, Apptronik, and Agility Robotics. The commercial exoskeleton business gives WIRobotics something most humanoid startups lack: a product already moving through real distribution channels while the moonshot matures.

Potential risks and opportunities

Risks

  • If humanoid development timelines slip past 2027, WIRobotics risks being outpaced by better-capitalized US and Chinese rivals who will have had more deployment cycles by then.
  • The North American expansion exposes WIRobotics to potential export-control scrutiny given South Korean hardware with Nvidia compute components entering US commercial channels.
  • Exoskeleton revenue concentration in Europe, China, Turkey, and Japan creates fragility if any single market shifts on regulatory approval or tariff conditions before the ALLEX line generates offsetting revenue.

Opportunities

  • Nvidia and AWS gain a live international robotics reference customer, strengthening their pitch to other humanoid hardware startups seeking cloud and GPU partnerships.
  • South Korean VCs (JB Investment, Hana Ventures, SBVA) are establishing a track record in humanoid infrastructure that positions them ahead of Western funds still circling the space.
  • Exoskeleton distributors already operating in Europe and Japan could accelerate WIRobotics' humanoid channel strategy by converting existing B2B relationships into early ALLEX research partnerships.

What we don't know yet

  • Whether the Nvidia and AWS collaborations involve specific hardware supply agreements or are limited to cloud and simulation infrastructure partnerships.
  • How WIRobotics plans to differentiate ALLEX in the humanoid market by 2027, given Figure, Apptronik, and 1X will also be in or near commercial deployment.
  • What regulatory or import pathways WIRobotics is navigating for US market entry from its new California office, particularly for medical-adjacent exoskeleton products.

Originally reported by prnewswire.com

Read the original article →

Original headline: WIRobotics Closes $68M Series B Led by JB Investment to Scale ALLEX Humanoid Platform and Wearable Exoskeleton Line With Nvidia and AWS Backing